NCT07654361
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Not Yet Recruiting
PHASE3Ages 18–79InterventionalTreatmentGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
~3,600 participants
Updated 2026-06-22 on ClinicalTrials.gov
What's tested:AleniglipronPlacebo
At a glance
Recruiting sites
0 of 71 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change in body weight from Baseline
Measured over Baseline and Week 76
Conditions
Where it's being run
71 sites across 32 statesFlorida7
Texas7
California6
North Carolina6
Georgia5
Arizona3
Missouri3
Alabama2
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Signed informed consent
BMI ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) and presence of ≥1 of the obesity related comorbidities.
Exclusion
Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.
Self-reported change in body weight \>5 kg within 3 months before Screening.
Have prior or planned surgical or non-surgical treatment for obesity.
Have or plan to have endoscopic and/or device-based therapy for obesity.
Have obesity induced by other endocrine disorders.
Impaired renal function at Screening
Chronic malabsorption
What this trial measures
- Percent change in body weight from BaselineBaseline and Week 76